A012103

This study will investigate whether adjuvant checkpoint inhibition offers any additional recurrence-free survival (RFS) benefit to early-stage Triple Negative Breast Cancer patients who achieve a pathologic Complete Response (pCR) after neoadjuvant chemotherapy with checkpoint inhibition. If there is no significant difference in RFS, then patients who achieve a pCR can avoid the additional toxicity, inconvenience, and cost of continued ICI treatment.